On the cellular therapy frontier, structure-guided CCL27-based CAR T cells targeting CCR10-expressing tumor cells, such as in multiple myeloma, have been described as promising candidates in early proof-of-concept (132). Here, CCL27 is linked to plasma cell myeloma.